PTC Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for PTC Therapeutics (PTCT).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

13Buy

2Hold

1Sell

Consensus RatingBuy# Analysts16Avg. Consensus PT$84Upside to Avg. PT+30.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$85→$75
Sep 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$130→$137
Sep 14, 2026	Leerink Partners	—	Assumes	Outperform	$98
Aug 14, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$120→$122
Aug 13, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$106→$109
Jul 31, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$93→$104
Jul 31, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$93→$106
Jul 20, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$95→$93
Jul 16, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$124→$130
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$82→$85
Jun 9, 2026	Citigroup	Geoff Meacham	Assumes	Neutral→Buy	$75→$108
May 27, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$76→$85
May 8, 2026	TD Cowen	Joseph Thome	Upgrade	Hold→Buy	$75→$90
May 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$81→$82
May 8, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$86→$95
Mar 30, 2026	Jefferies	Faisal Khurshid	Downgrade	Buy→Hold	$91→$76
Feb 23, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$90→$92
Feb 20, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$93→$86
Feb 20, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$87→$82
Feb 20, 2026	B of A Securities	Tazeen Ahmad	PT Cut	Buy	$97→$93

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.

Benzinga Newsdesk

PTC Therapeutics Inc

PTC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

People Also Watch

People Also Watch

PTC Therapeutics Inc

PTC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PROCantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PROBarclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PROWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PROMorgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PROWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106